Results 181 to 190 of about 7,856 (243)

Inflammation in preschool cystic fibrosis is of mixed phenotype, extends beyond the lung and is differentially modified by CFTR modulators. [PDF]

Thorax
Shanthikumar S, Gubbels L, Wong ATC, Walker H, Ranganathan SC, Neeland MR.   +5 more
europepmc   +1 more source

Treatment effects of CFTR modulators on people with cystic fibrosis carrying the Q359K/T360K variant. [PDF]

ERJ Open Res
Yaacoby-Bianu K, Heching M, Kramer MR, Shmueli E, Prais D, Vermeulen F, Ramalho AS, Cohen R, Livnat G, Shteinberg M.   +9 more
europepmc   +1 more source

Efficacy and safety of CFTR modulators in patients with interstitial lung disease caused by ABCA3 transporter deficiency. [PDF]

ERJ Open Res
Le Brun M, Nathan N, Louvrier C, Legendre M, Feuillet S, Frija-Masson J, Onanga M, Morer L, Debray MP, Fajac I, Burgel PR, Marchand-Adam S, Crestani B, Borie R.   +13 more
europepmc   +1 more source

Strength-Oriented Virtual Exercise Training Intervention in Children and Adolescents with Cystic Fibrosis Under CFTR Modulators (the FIQMODE Study): Study Protocol for a Randomized Controlled Trial. [PDF]

Curr Protoc
Pantoja-Arévalo L, Yvert T, Iturriaga T, Sanz-Santiago V, Barceló O, Quesada-González C, Morales-Tirado A, Santiago-Dorrego C, López-Neyra A, Ruiz de Valbuena M, De Manuel Gómez C, Rubio Alonso M, De Vidania S, Ramírez-Castillejo C, González-Gross M, Pérez-Ruiz M.   +15 more
europepmc   +1 more source

Clinical Outcomes in Patients with Cystic Fibrosis Receiving CFTR Modulators: A Comparison of Childhood Versus Adolescent Initiation. [PDF]

Children (Basel)
Toraih EA, Malik HA, Islam RK, Pirzadah HA, Abdelmaksoud A, Elshazli RM, Boasiako PA, Alenazi SA, Dabel A, Jishu JA, Alenezi BT, Aiash H, Fawzy MS.   +12 more
europepmc   +1 more source

Pharmacokinetic variability of CFTR modulators from standard and alternative regimens. [PDF]

Pulm Pharmacol Ther
Rose NR, Chalamalla AR, Garcia BA, Krick S, Bergeron J, Sadeghi H, Schellhase DE, Ryan KJ, Dowell AE, Acosta EP, Guimbellot JS.   +10 more
europepmc   +1 more source

Allergic Bronchopulmonary Aspergillosis (ABPA) in the Era of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators. [PDF]

J Fungi (Basel)
Chatterjee P, Moss CT, Omar S, Dhillon E, Hernandez Borges CD, Tang AC, Stevens DA, Hsu JL.   +7 more
europepmc   +1 more source

Beyond the 10%: Unraveling the genetic diversity in Turkish cystic fibrosis patients not eligible for CFTR modulators. [PDF]

Pediatr Pulmonol
Yıldız CA, Selçuk Balcı M, Karabulut Ş, Başer ZM, Yüksel Kalyoncu M, Metin Çakar N, Akkitap Yiğit MM, Baysal EE, Özdemircioğlu F, Uzunoğlu B, Taştan G, Ergenekon P, Gökdemir Y, Erdem Eralp E, Karakoç F, Ata P, Karadağ B.   +16 more
europepmc   +1 more source

Lentiviral vector gene therapy and CFTR modulators show comparable effectiveness in cystic fibrosis rat airway models. [PDF]

Gene Ther
McCarron A, Ling KM, Montgomery ST, Martinovich KM, Cmielewski P, Rout-Pitt N, Kicic A, Parsons D, Donnelley M.   +8 more
europepmc   +1 more source

Allergic bronchopulmonary aspergillosis as an initial manifestation of cystic fibrosis: Diagnostic and therapeutic implications in the era of CFTR modulators. [PDF]

J Allergy Clin Immunol Glob
Mitropoulou G, Balmpouzis Z, Oberhansli-Wavre A, Morris M, Blanchon S, Sauty A, Koutsokera A.   +6 more
europepmc   +1 more source